Pathology

 activation mutation
 overexpression

• fusion gene in which the promoter region of genes coding for the subunits of immunoglobulins (IGHG1, IGLC1, IGKC) or TCR (TCRA, TCRB, TCRC, TCRD) are juxtaposed to the entire coding sequence of a second gene that is subsequently overexpressed in lymphoid cells causing lymphomas or lymphoid leukemias

• fusion gene in which the promoter region of a first gene is juxtaposed to the entire coding sequence of a second gene that is subsequently overexpressed in specific tissue

References

 Hammond SM. MicroRNAs as oncogenes. Curr Opin Genet Dev. 2006 Feb;16(1):4-9. PMID: #16361094#

 Prive GG, Melnick A. Specific peptides for the therapeutic targeting of oncogenes. Curr Opin Genet Dev. 2006 Feb;16(1):71-7. PMID: #16377176#

 Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004 Aug;10(8):789-99. PMID: #15286780#

 Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman N, Stratton MR. A census of human cancer genes. Nat Rev Cancer. 2004 Mar;4(3):177-83. PMID: #14993899#

 Felsher DW. Reversibility of oncogene-induced cancer. Curr Opin Genet Dev. 2004 Feb;14(1):37-42. PMID: #15108803#

 Felsher DW. Cancer revoked: oncogenes as therapeutic targets. Nat Rev Cancer. 2003 May;3(5):375-80. PMID: #12724735#

 Hueber AO, Evan GI. Traps to catch unwary oncogenes. Trends Genet. 1998 Sep;14(9):364-7. PMID: #9769732#